Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Inhibition of MEK to Treat Cancer: Focus on Melanoma

J. Larkin describes key molecular pathways in melanoma, focussing on RAS-RAF-MEK-ERK. He describes NRAS-driven and other molecularly defined subgroups, MEK as a therapeutic target, data with MEK inhibitors including combinations with BRAFi, and early data in uveal melanoma.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings